SHANGHAI, Nov. 30, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient was dosed in NCT05468489, a bridging head-to-head trial in the United States comparing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results